Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, Freeman GJ, Boland GM, Luster AD.

Immunity. 2019 Jun 18;50(6):1498-1512.e5. doi: 10.1016/j.immuni.2019.04.010. Epub 2019 May 13.

PMID:
31097342
2.

Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis.

Guillerey C, Chow MT, Miles K, Olver S, Sceneay J, Takeda K, Möller A, Smyth MJ.

Oncoimmunology. 2015 Apr 2;4(9):e1027468. eCollection 2015 Sep.

3.

Chemokines in cancer.

Chow MT, Luster AD.

Cancer Immunol Res. 2014 Dec;2(12):1125-31. doi: 10.1158/2326-6066.CIR-14-0160. Review.

4.

CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

Paget C, Chow MT, Gherardin NA, Beavis PA, Uldrich AP, Duret H, Hassane M, Souza-Fonseca-Guimaraes F, Mogilenko DA, Staumont-Sallé D, Escalante NK, Hill GR, Neeson P, Ritchie DS, Dombrowicz D, Mallevaey T, Trottein F, Belz GT, Godfrey DI, Smyth MJ.

Immunol Cell Biol. 2015 Feb;93(2):198-212. doi: 10.1038/icb.2014.94. Epub 2014 Nov 11.

5.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
6.

Type I NKT-cell-mediated TNF-α is a positive regulator of NLRP3 inflammasome priming.

Chow MT, Duret H, Andrews DM, Faveeuw C, Möller A, Smyth MJ, Paget C.

Eur J Immunol. 2014 Jul;44(7):2111-20. doi: 10.1002/eji.201344329. Epub 2014 Apr 29.

7.

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.

Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ.

Nat Immunol. 2014 May;15(5):431-8. doi: 10.1038/ni.2850. Epub 2014 Mar 23.

PMID:
24658051
8.

Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis.

Romain G, Tremblay S, Arena ET, Antunes LC, Covey S, Chow MT, Finlay BB, Menendez A.

BMC Microbiol. 2013 Oct 29;13:238. doi: 10.1186/1471-2180-13-238.

9.

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ, Darcy PK.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6. doi: 10.1073/pnas.1308209110. Epub 2013 Aug 20.

10.

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK.

Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.

11.

NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma.

Chow MT, Tschopp J, Möller A, Smyth MJ.

Immunol Cell Biol. 2012 Nov;90(10):983-6. doi: 10.1038/icb.2012.46. Epub 2012 Sep 25.

PMID:
23010873
12.

NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases.

Chow MT, Sceneay J, Paget C, Wong CS, Duret H, Tschopp J, Möller A, Smyth MJ.

Cancer Res. 2012 Nov 15;72(22):5721-32. doi: 10.1158/0008-5472.CAN-12-0509. Epub 2012 Sep 17.

13.

Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche.

Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, Sloan EK, Parker BS, Bowtell DD, Smyth MJ, Möller A.

Cancer Res. 2012 Aug 15;72(16):3906-11. doi: 10.1158/0008-5472.CAN-11-3873. Epub 2012 Jul 2.

14.

Role of γδ T cells in α-galactosylceramide-mediated immunity.

Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ.

J Immunol. 2012 Apr 15;188(8):3928-39. doi: 10.4049/jimmunol.1103582. Epub 2012 Mar 12.

15.

Inflammation and immune surveillance in cancer.

Chow MT, Möller A, Smyth MJ.

Semin Cancer Biol. 2012 Feb;22(1):23-32. doi: 10.1016/j.semcancer.2011.12.004. Epub 2011 Dec 24. Review.

PMID:
22210181
16.

Homeostatic defects in interleukin 18-deficient mice contribute to protection against the lethal effects of endotoxin.

Andrews DM, Chow MT, Ma Y, Cotterell CL, Watt SV, Anthony DA, Akira S, Iwakura Y, Trapani JA, Zitvogel L, Smyth MJ.

Immunol Cell Biol. 2011 Aug;89(6):739-46. doi: 10.1038/icb.2010.168. Epub 2011 Jan 25.

PMID:
21263463
17.

H2-M3-restricted CD8+ T cells augment CD4+ T-cell responses by promoting DC maturation.

Chow MT, Teh HS.

Eur J Immunol. 2010 May;40(5):1408-17. doi: 10.1002/eji.200939934.

18.

RasGRP1 regulates antigen-induced developmental programming by naive CD8 T cells.

Priatel JJ, Chen X, Huang YH, Chow MT, Zenewicz LA, Coughlin JJ, Shen H, Stone JC, Tan R, Teh HS.

J Immunol. 2010 Jan 15;184(2):666-76. doi: 10.4049/jimmunol.0803521. Epub 2009 Dec 9.

19.

TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.

Kim EY, Teh SJ, Yang J, Chow MT, Teh HS.

J Immunol. 2009 Nov 15;183(10):6051-7. doi: 10.4049/jimmunol.0803482. Epub 2009 Oct 19.

20.

Preferential development of CD4 and CD8 T regulatory cells in RasGRP1-deficient mice.

Chen X, Priatel JJ, Chow MT, Teh HS.

J Immunol. 2008 May 1;180(9):5973-82.

21.

H2-M3-restricted T cells participate in the priming of antigen-specific CD4+ T cells.

Chow MT, Dhanji S, Cross J, Johnson P, Teh HS.

J Immunol. 2006 Oct 15;177(8):5098-104.

22.
23.

Metabolic alkalosis in a hemodialysis patient after ingestion of a large amount of an antacid medication.

Sahani MM, Brennan JF, Nwakanma C, Chow MT, Ing TS, Leehey DJ.

Artif Organs. 2001 Apr;25(4):313-5.

PMID:
11318761
24.

Relapsing polychondritis.

Chow MT, Anderson SF.

Optom Vis Sci. 2000 Jun;77(6):286-92.

PMID:
10879785
25.
26.

Use of a phosphorus-enriched hemodialysate to prevent hypophosphatemia in a patient with renal failure-related pericarditis.

Emelife-Obi C, Chow MT, Qamar-Rohail H, Leehey DJ, Gandhi VC, Ing TS.

Clin Nephrol. 1998 Aug;50(2):131-3.

PMID:
9725787
27.

Treatment of acute methanol intoxication with hemodialysis using an ethanol-enriched, bicarbonate-based dialysate.

Chow MT, Di Silvestro VA, Yung CY, Nawab ZM, Leehey DJ, Ing TS.

Am J Kidney Dis. 1997 Oct;30(4):568-70.

PMID:
9328374
28.

Use of a phosphorus-enriched dialysate to hemodialyze patients with ethylene glycol intoxication.

Chow MT, Chen J, Patel JS, Ali S, Noghnogh AA, Leehey DJ, Ing TS.

Int J Artif Organs. 1997 Feb;20(2):101-4.

PMID:
9093888
29.

Effect of phototherapy on neonatal riboflavin status.

Tan KL, Chow MT, Karim SM.

J Pediatr. 1978 Sep;93(3):494-7. No abstract available.

PMID:
690775
30.

Immobilized enzyme catalysis with reaction-generated pH change.

Bailey JE, Chow MT.

Biotechnol Bioeng. 1974 Oct;16(10):1345-57. No abstract available.

PMID:
4429793

Supplemental Content

Support Center